Lycia Therapeutics
South San Francisco
About Lycia Therapeutics
Lycia Therapeutics is the operator of a biotechnology firm that aims to research and produce first-in-class therapies. The company's lysosomal targeting chimeras (LYTACs) platform is used to develop therapeutics that degrade extracellular and membrane-bound proteins that drive a variety of difficult-to-treat diseases, such as cancer and autoimmune conditions, allowing doctors to obtain drugs to cure patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $226.6M
- Funding stage: Late Stage Venture
- Last round: Series C (May 2024)
- Website: lyciatx.com
- Phone: (650) 686-8821
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/lycia-therapeutics-79542 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.